Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2011, Article ID 937843, 8 pages
http://dx.doi.org/10.1155/2011/937843
Review Article

Targeting Nuclear Hormone Receptors: PPARα Agonists as Potential Disease-Modifying Drugs for Rheumatoid Arthritis

Laboratory of Clinical Immunopharmacology, Scientific Research Institute of Clinical Immunology, RAMS, 14 Yadrintsevskaya Street, Novosibirsk 630099, Russia

Received 30 December 2010; Revised 12 April 2011; Accepted 26 April 2011

Academic Editor: Malcolm Smith

Copyright © 2011 Ivan V. Shirinsky and Valery S. Shirinsky. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Nuclear Receptors Nomenclature Committee, “A unified nomenclature system for the nuclear receptor superfamily,” Cell, vol. 97, no. 2, pp. 161–163, 1999. View at Google Scholar
  2. S. R. Pyper, N. Viswakarma, S. Yu, and J. K. Reddy, “PPARalpha: energy combustion, hypolipidemia, inflammation and cancer,” Nuclear Receptor Signaling, vol. 8, no. 16, article e002, 2010. View at Google Scholar
  3. L. Michalik, J. Auwerx, J. P. Berger et al., “International union of pharmacology. LXI. Peroxisome proliferator-activated receptors,” Pharmacological Reviews, vol. 58, no. 4, pp. 726–741, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. M. V. Chakravarthy, Z. Pan, Y. Zhu et al., ““New” hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis,” Cell Metabolism, vol. 1, no. 5, pp. 309–322, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. S. E. Gabriel, “Cardiovascular morbidity and mortality in rheumatoid arthritis,” American Journal of Medicine, vol. 121, no. 10, supplement 1, pp. S9–S14, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. N. Rotman and W. Wahli, “Fatty acid synthesis and PPARalpha hand in hand,” Chemistry and Biology, vol. 16, no. 8, pp. 801–802, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. A. Shah, D. J. Rader, and J. S. Millar, “The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans,” Atherosclerosis, vol. 210, no. 1, pp. 35–40, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. A. G. Semb, T. K. Kvien, A. H. Aastveit et al., “Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the apolipoprotein-related mortality RISk (AMORIS) study,” Annals of the Rheumatic Diseases, vol. 69, no. 11, pp. 1996–2001, 2010. View at Google Scholar
  9. C. Straczek, M. Tafflet, P. Barberger-Gateau et al., “Do lipids and apolipoproteins predict coronary heart disease under statin and fibrate therapy in the primary prevention setting in community-dwelling elderly subjects? The 3C Study,” Atherosclerosis, vol. 214, no. 2, pp. 426–431, 2011. View at Google Scholar
  10. J. F. Boyer, P. A. Gourraud, A. Cantagrel, J. L. Davignon, and A. Constantin, “Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis,” Joint, Bone, Spine, vol. 78, no. 2, pp. 179–183, 2011. View at Google Scholar
  11. C. Foucher, L. Brugere, J. C. Ansquer et al., “Fenofibrate, homocysteine and renal function,” Current Vascular Pharmacology, vol. 8, no. 5, pp. 589–603, 2010. View at Google Scholar
  12. D. Liao, H. Tan, R. Hui et al., “Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I protein synthesis and enhancing HDL cholesterol clearance,” Circulation Research, vol. 99, no. 6, pp. 598–606, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. M. R. Taskinen, D. R. Sullivan, C. Ehnholm et al., “Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 6, pp. 950–955, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. N. Vuilleumier, J. Bratt, R. Alizadeh, T. Jogestrand, I. Hafstrom, and J. Frostegard, “Anti-apoA-1 IgG and oxidized LDL are raised in rheumatoid arthritis (RA): potential associations with cardiovascular disease and RA disease activity,” Scandinavian Journal of Rheumatology, vol. 39, no. 6, pp. 447–453, 2010. View at Google Scholar
  15. O. Mayer Jr., J. Šimon, L. Holubec, R. Pikner, and L. Trefil, “Folate co-administration improves the effectiveness of fenofibrate to decrease the lipoprotein oxidation and endothelial dysfunction surrogates,” Physiological Research, vol. 55, no. 5, pp. 475–481, 2006. View at Google Scholar · View at Scopus
  16. S. Berglund, A. Södergren, S. Wållberg Jonsson, and S. Rantapää Dahlqvist, “Atherothrombotic events in rheumatoid arthritis are predicted by homocysteine—a six-year follow-up study,” Clinical and Experimental Rheumatology, vol. 27, no. 5, pp. 822–825, 2009. View at Google Scholar · View at Scopus
  17. J. M. Abraham and L. Cho, “The homocysteine hypothesis: still relevant to the prevention and treatment of cardiovascular disease?” Cleveland Clinic Journal of Medicine, vol. 77, no. 12, pp. 911–918, 2010. View at Google Scholar
  18. S. Abourbih, K. B. Filion, L. Joseph et al., “Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review,” American Journal of Medicine, vol. 122, no. 10, pp. e961–e968, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. J. Sasaki, K. Yamamoto, and M. Ageta, “Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: a randomized, double-blind, placebo-controlled, multicenter, crossover study,” Clinical Therapeutics, vol. 24, no. 10, pp. 1614–1626, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Dierkes, C. Luley, and S. Westphal, “Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels,” Vascular Health and Risk Management, vol. 3, no. 1, pp. 99–108, 2007. View at Google Scholar · View at Scopus
  21. P. R. Colville-Nash, S. S. Qureshi, D. Willis, and D. A. Willoughby, “Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: correlation with induction of heme oxygenase 1,” Journal of Immunology, vol. 161, no. 2, pp. 978–984, 1998. View at Google Scholar · View at Scopus
  22. N. Marx, G. K. Sukhova, T. Collins, P. Libby, and J. Plutzky, “PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells,” Circulation, vol. 99, no. 24, pp. 3125–3131, 1999. View at Google Scholar · View at Scopus
  23. Y. Rival, L. Puech, T. Taillandier et al., “PPAR activators and COX inhibitors selectively block cytokine-induced COX-2 expression and activity in human aortic smooth muscle cells,” European Journal of Pharmacology, vol. 606, no. 1–3, pp. 121–129, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. B. Staels, W. Koenig, A. Habib et al., “Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators,” Nature, vol. 393, no. 6687, pp. 790–793, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. G. Chinetti, S. Griglio, M. Antonucci et al., “Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages,” The Journal of Biological Chemistry, vol. 273, no. 40, pp. 25573–25580, 1998. View at Google Scholar
  26. A. Madej, B. Okopien, J. Kowalski et al., “Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb,” International Journal of Clinical Pharmacology and Therapeutics, vol. 36, no. 6, pp. 345–349, 1998. View at Google Scholar · View at Scopus
  27. R. Belfort, R. Berria, J. Cornell, and K. Cusi, “Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 2, pp. 829–836, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. P. Delerive, K. De Bosscher, S. Besnard et al., “Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1,” The Journal of Biological Chemistry, vol. 274, no. 45, pp. 32048–32054, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Delerive, P. Gervois, J. C. Fruchart, and B. Staels, “Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators,” The Journal of Biological Chemistry, vol. 275, no. 47, pp. 36703–36707, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. P. R. Devchand, H. Keller, J. M. Peters, M. Vazquez, F. J. Gonzalez, and W. Wahli, “The PPARalpha-leukotriene B4 pathway to inflammation control,” Nature, vol. 384, no. 6604, pp. 39–43, 1996. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. H. Okamoto, T. Iwamoto, S. Kotake, S. Momohara, H. Yamanaka, and N. Kamatani, “Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 23, no. 3, pp. 323–330, 2005. View at Google Scholar · View at Scopus
  32. J. W. Lee, P. J. Bajwa, M. J. Carson et al., “Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10-deficient mice,” Gastroenterology, vol. 133, no. 1, pp. 108–123, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. S. Maruyama, K. Kato, M. Kodama et al., “Fenofibrate, a peroxisome proliferator-activated receptor alpha activator, suppresses experimental autoimmune myocarditis by stimulating the interleukin-10 pathway in rats,” Journal of Atherosclerosis and Thrombosis, vol. 9, no. 2, pp. 87–92, 2002. View at Google Scholar · View at Scopus
  34. T. Lemberger, R. Saladin, M. Vázquez et al., “Expression of the peroxisome proliferator-activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm,” The Journal of Biological Chemistry, vol. 271, no. 3, pp. 1764–1769, 1996. View at Publisher · View at Google Scholar · View at Scopus
  35. K. De Bosscher, W. Vanden Berghe, and G. Haegeman, “Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors,” Journal of Neuroimmunology, vol. 109, no. 1, pp. 16–22, 2000. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Riccardi, E. Mazzon, S. Bruscoli et al., “Peroxisome proliferator-activated receptor-alpha modulates the anti-inflammatory effect of glucocorticoids in a model of inflammatory bowel disease in mice,” Shock, vol. 31, no. 3, pp. 308–316, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. N. Bougarne, R. Paumelle, S. Caron et al., “PPARalpha blocks glucocorticoid receptor alpha-mediated transactivation but cooperates with the activated glucocorticoid receptor alpha for transrepression on NF-kappaB,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 18, pp. 7397–7402, 2009. View at Google Scholar
  38. A. E. Koch, “The role of angiogenesis in rheumatoid arthritis: recent developments,” Annals of the Rheumatic Diseases, vol. 59, supplement 1, pp. i65–i71, 2000. View at Google Scholar · View at Scopus
  39. J. Varet, L. Vincent, P. Mirshahi et al., “Fenofibrate inhibits angiogenesis in vitro and in vivo,” Cellular and Molecular Life Sciences, vol. 60, no. 4, pp. 810–819, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. D. Panigrahy, A. Kaipainen, S. Huang et al., “PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 3, pp. 985–990, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. A. Katayama, Y. Yamamoto, K. Tanaka et al., “Fenofibrate enhances neovascularization in a murine ischemic hindlimb model,” Journal of Cardiovascular Pharmacology, vol. 54, no. 5, pp. 399–404, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. F. Biscetti, E. Gaetani, A. Flex et al., “Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism,” Diabetes, vol. 57, no. 5, pp. 1394–1404, 2008. View at Google Scholar
  43. F. Biscetti, G. Straface, D. Pitocco, F. Zaccardi, G. Ghirlanda, and A. Flex, “Peroxisome proliferator-activated receptors and angiogenesis,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 19, no. 11, pp. 751–759, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. Z. Szekanecz, T. Besenyei, A. Szentpetery, and A. E. Koch, “Angiogenesis and vasculogenesis in rheumatoid arthritis,” Current Opinion in Rheumatology, vol. 22, no. 3, pp. 299–306, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. T. Benameur, S. Tual-Chalot, R. Andriantsitohaina, and M. C. Martinez, “PPARalpha is essential for microparticle-induced differentiation of mouse bone marrow-derived endothelial progenitor cells and angiogenesis,” PLoS One, vol. 5, no. 8, Article ID e12392, 2010. View at Google Scholar
  46. N. Leuenberger, S. Pradervand, and W. Wahli, “Sumoylated PPARalpha mediates sex-specific gene repression and protects the liver from estrogen-induced toxicity in mice,” The Journal of Clinical Investigation, vol. 119, no. 10, pp. 3138–3148, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. S. E. Dunn, S. S. Ousman, R. A. Sobel et al., “Peroxisome proliferator-activated receptor (PPAR)alpha expression in T cells mediates gender differences in development of T cell-mediated autoimmunity,” Journal of Experimental Medicine, vol. 204, no. 2, pp. 321–330, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. H. Okamoto and N. Kamatani, “Successful treatment with fenofibrate, a peroxisome proliferator activated receptor alpha ligand, for a patient with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 63, no. 8, pp. 1002–1003, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. M. Goto, “A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis,” Modern Rheumatology, vol. 20, no. 3, pp. 238–243, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus